Discovery of novel imidazo[4,5- b ]pyridines as potent and selective inhibitors of phosphodiesterase 10A (PDE10A)

ACS Medicinal Chemistry Letters

Volumn 5, Issue 6, 2014, Pages 700-705

  Hu, Essa ^a   Andrews, Kristin ^a   Chmait, Samer ^a   Zhao, Xiaoning ^a   Davis, Carl ^b   Miller, Silke ^b   Hill Della Puppa, Geraldine ^b   Dovlatyan, Mary ^b   Chen, Hang ^a   Lester Zeiner, Dianna ^a   Able, Jessica ^a   Biorn, Christopher ^a   Ma, Ji ^b   Shi, Jianxia ^b   Treanor, James ^b   Allen, Jennifer R ^a  

^a Department of Medicinal Chemistry ^*  (United States)

^b AMGEN INC   (United States)

Author keywords

bioavailability; Phosphodiesterase 10A; receptor occupancy; schizophrenia

Indexed keywords

IMIDAZO[4,5 B]PYRIDINE DERIVATIVE; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 84902484994     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5000993     Document Type: Article

References (10)

1. Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development Nat. Rev. Drug Discovery 2006, 5, 660-670
2. Hebb, A. L. O.; Robertson, H. A. Role of phosphodiesterases in neurological and psychiatric disease Curr. Opin. Pharmacol. 2007, 7, 86-92
3. Halene, T. B.; Siegel, S. J. PDE Inhibitors in psychiatry: future options for dementia, depression, and schizophrenia? Drug Discovery Today 2007, 12, 870-878
4. Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Libeman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol. Psychiatry 2006, 10, 79-104
5. Menniti, F. S.; Chappie, T. A.; Humphrey, J. M.; Schmidt, C. J. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia Curr. Opin. Invest. Drugs 2007, 8, 54-59
6. Siuciak, J. A.; McCarthy, S. A.; Chapin, D. S.; Fujiwara, R. A.; James, L. C.; Williams, R. D.; Stock, J. L.; McNeish, J. D.; Strick, C. A.; Menniti, F. S.; Schmidt, C. J. Genetic deletion of the striatum-enriched phosphodiester PDE10A: evidence for altered striatal function Neuropharmacology 2006, 51, 374-385
7. Kehler, J.; Nielsen, J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia Curr. Pharm. Des. 2011, 17, 137-150
8. Hu, E.; Kunz, R. K.; Chen, N.; Rumfelt, S.; Siegmund, A.; Andrews, K.; Chmait, S.; Zhao, S.; Davis, C.; Chen, H.; Lester-Zeiner, D.; Ma, J.; Biorn, C.; Shi, J.; Porter, A.; Treanor, J.; Allen, J. R. Design, optimization, and biological evaluation of novel ketobenzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A) J. Med. Chem. 2013, 56, 8781-8792
9. Thomas, V. H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C. L.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective Expert Opin. Drug Metab. 2006, 4, 591-608
10. Hu, E.; Ma, J.; Biorn, C.; Lester-Zeiner, D.; Cho, R.; Rumfelt, S.; Kunz, R. K.; Nixey, T.; Michelsen, K.; Miller, S.; Shi, J.; Wong, J.; Hill Della Puppa, G.; Able, J.; Talreja, S.; Hwang, D.-R.; Hitchcock, S. A.; Porter, A.; Immke, D.; Allen, J. R.; Treanor, J.; Chen, H. Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer J. Med. Chem. 2012, 55, 4776-4787